MorphoSys reports updated ORR of 58% for MOR208 in DLBCL

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) reported that MOR208 plus Revlimid lenalidomide led to a 58% overall response rate (ORR) among 81 evaluable patients with relapsed or refractory diffuse large B cell lymphoma in the Phase II L-MIND trial. The updated data were released in an abstract ahead of next month’s American Society of Hematology meeting.

In March, MorphoSys reported that the combo led to an ORR of 49% in 68 evaluable patients. The company has said it plans to submit a rolling BLA to FDA in 2H19 for MOR208 (see "MorphoSys Planning BLA for DLBCL Candidate on Phase II Data")...